BlendsCJC-1295 + IpamorelinCJC/Ipa

CJC-1295 / Ipamorelin Blend

Fixed-ratio growth-hormone blend · CJC-1295 (no DAC) 5 mg + Ipamorelin 5 mg

The CJC-1295 / Ipamorelin blend is a pre-mixed, single-vial pairing of the two peptides that make up the classic growth-hormone stack — 5 mg of CJC-1295 in its short-acting no-DAC form (chemically Mod-GRF 1-29) and 5 mg of Ipamorelin, sold as one 10 mg powder in a fixed 1 : 1 ratio. Unlike the repair blends, this pairing has a real mechanistic rationale rather than pure convenience: CJC-1295 is an agonist at the GHRH receptor and Ipamorelin is an agonist at GHS-R1a, the ghrelin receptor — two different receptors on the same pituitary somatotroph, which is how the body's own two-signal GH release works. One identity check matters more here than on any other blend page: a 1 : 1 daily vial only makes sense with the no-DAC form, because the long-acting DAC molecule (CJC-1295 with DAC) is a chemically different compound dosed roughly 1–2 mg once weekly, and it owns essentially all of CJC-1295's human trial evidence. No published study has tested the co-formulated vial; the no-DAC form has no primary human trial, and Ipamorelin's human data are intravenous, with its Phase II trial failing its efficacy endpoint. Neither component is an approved drug, and both are prohibited in sport at all times (WADA S2).

TL;DRThe whole page · in 30 seconds

GH support · Lean body composition · Recovery · Two peptides, one shot

The classic growth-hormone stack in one vial. CJC-1295 (no DAC) works the GHRH receptor and Ipamorelin works the ghrelin receptor — two different switches on the same pituitary cell, fired together for a bigger GH pulse than either lands alone. 5 mg of each, one bedtime shot.

The basics

A pre-mixed powder: 5 mg CJC-1295 (no DAC / Mod-GRF 1-29) + 5 mg Ipamorelin — a 1 : 1 ratio, 10 mg per vial. One vial, one draw, both peptides every time.
The canonical GHRH + GHRP pairing — the one blend whose two peptides were designed to be injected together. CJC-1295 carries the GHRH signal; Ipamorelin carries the ghrelin-receptor signal.

Why people use it

A bigger pulse than either half alone — two receptors on the same somatotroph, fired at once, is exactly how the body triggers its own GH bursts.
Raises your own GH instead of injecting it — the pituitary keeps its natural rhythm and feedback in the loop.
The clean GHRP half — Ipamorelin skips the appetite and prolactin spike that make GHRP-2 and GHRP-6 harder to run.
Leaner composition, better recovery, deeper sleep — the GH/IGF-1 goals people run this pair for, in a single nightly draw.

How to run it

Dose: 8 units a day (400 mcg of blend = 200 mcg CJC-1295 no-DAC + 200 mcg Ipamorelin); 4 units to start
How often: Once daily — some run 2–3× daily, adding a fasted morning and/or pre-workout shot
How: A small injection under the skin (belly fat) — one syringe covers both
When: Bedtime, on an empty stomach — keep ~2 hours clear of food
Cycle: 8–12 weeks on, then 4–6 weeks off (one vial at 8 units is ~25 doses, about 3–4 weeks)

Stacks well with

BPC-157 + TB-500 — or the pre-mixed Wolverine Blend / GLOW Blend — local tissue repair under the systemic GH backdrop; a different lever, so it adds instead of doubling up.
Nothing else off the GH shelf — a second GHRH analog (Tesamorelin, Sermorelin) or a second GHRP (GHRP-2, GHRP-6) is the same lever twice; this vial already carries one of each.

Good to know

Empty stomach is the rule that matters — a meal raises insulin and somatostatin (GH's off-switch) and wastes the pulse. Keep ~2 hours clear either side, and dose at bedtime to ride the body's biggest natural GH burst in deep sleep.
Check the label says no DAC. A 1 : 1 blend only works with the short-acting no-DAC form — the DAC form is dosed once weekly, which would cram a week of Ipamorelin into a single shot. If your vial says "with DAC," this page's schedule and math don't apply to it.
GH transiently raises blood sugar and lowers insulin sensitivity, so watch glucose on a longer run.
Banned in tested sport — both halves are on the WADA list (S2).
You can't move one peptide without moving the other: the vial fixes the 1 : 1, so the only lever is the whole dose. Separate vials are the answer when you want a different split.

Bottom line: The one-vial version of the classic bedtime GH stack — 8 units fasted before bed, in 8–12-week blocks, from a vial whose label says no DAC.

Molecular identity

Specs

Composition: CJC-1295 (no DAC / Mod-GRF 1-29) 5 mg · Ipamorelin 5 mg = 10 mg per vialCross-source vendor agreement
Ratio: 1 : 1 by mass — 50 % CJC-1295 (no DAC) · 50 % IpamorelinCalculated
Structure / class: Fixed-ratio, co-lyophilized blend of a GHRH analog and a GHRP in one vial — not a new molecule; each component keeps its own identity and pharmacologyCross-source vendor agreement
Components: CJC-1295 no-DAC = Mod-GRF(1-29): C152H252N44O42 · 3,367.9 g/mol (monoiso 3,365.89 Da) — Ipamorelin: C38H49N9O5 · 711.9 g/mol (monoiso 711.39 Da) · Aib-His-D-2-Nal-D-Phe-Lys-NH₂ · CAS 170851-70-4 · UNII Y9M3S784Z6PubChem CID 91976842 · PubChem CID 9831659
No-DAC form: This blend is the no-DAC form. The DAC molecule is different — CJC-1295 with DAC (DAC:GRF): C165H269N47O46 · 3,647.2 g/mol · CAS 446262-90-4 · UNII 62RC32V9N7 — and is dosed once weekly, so a 1 : 1 daily Ipamorelin vial labeled "with DAC" is a schedule mismatch this page's math does not coverPubChem CID 91971820
Molecular target: Two receptors on the same pituitary somatotroph: the GHRH receptor (GHRHR) and GHS-R1a, the ghrelin receptorPMID 16352683 · PMID 9849822
Half-life: No single clock — ~30 min for CJC-1295 no-DAC (secondary-sourced) and ~2 h for Ipamorelin (human IV, terminal); the ~5.8–8.1 days often quoted for "CJC-1295" belongs to the DAC molecule, which is not in this vialPMID 10496658 · PMID 16352683Half-life curve →
Regulatory status: Neither component is an approved drug; no trial has tested the co-formulated blend; both are prohibited in sport (WADA S2, at all times)FDA / WADA Prohibited List

Plain English

Mechanism

A blend is a packaging decision, not a new drug. This vial is one freeze-dried powder containing two separate peptides, so adding water puts both in solution together and every draw carries them in the vial's fixed proportions — 5 parts CJC-1295 to 5 parts Ipamorelin by weight, which is why 1 unit on a U-100 syringe at the standard 10 mg + 2 mL mix delivers 50 mcg of blend: 25 mcg of each. Nothing about the co-formulation changes how either peptide works; it changes only how you measure them. Neither molecular formula contains sulfur and there is no metal in the vial, so the storage question is the ordinary one for any reconstituted peptide rather than a blend-specific chemistry problem — nobody has published stability data on the mixed solution, so keep it cold and finish it within about four weeks, which at the common dose is roughly one vial anyway.

Which CJC-1295 is actually in the vial is the first thing to settle, because the name covers two chemically distinct molecules. The long-acting form carries a Drug Affinity Complex — a maleimidopropionamide hook that binds covalently to cysteine-34 on serum albumin, stretching GHRH's minutes-long half-life to roughly 5.8–8.1 days in humans and putting it on a once-weekly schedule at ~1–2 mg. The short-acting form leaves the linker off and is a different compound entirely: Mod-GRF(1-29), C152H252N44O42, 3,367.9 g/mol, reported to clear in about 30 minutes (a secondary-sourced figure, not a published pharmacokinetic trial), dosed at 100 mcg one to three times daily and always paired with a GHRP. Blends are the no-DAC form, and the reason is arithmetic rather than preference: a 1 : 1 vial dosed on the DAC form's weekly schedule would deliver a week's worth of Ipamorelin in a single injection. If a vendor's label on a 1 : 1 Ipamorelin blend says "with DAC," the two schedules are incompatible and none of this page's math applies to it.

CJC-1295 supplies the GHRH signal. It is an agonist at the GHRH receptor on the somatotroph cells — the growth-hormone-producing cells — of the anterior pituitary; binding drives the cAMP/PKA pathway, which stimulates both the synthesis and the pulsatile release of growth hormone, the same signal native GHRH carries. Read the evidence level carefully here: the human trials belong to the DAC molecule, where a single subcutaneous dose raised mean GH several-fold for at least six days and IGF-1 for over a week, and continuous stimulation preserved GH pulse frequency and amplitude while lifting the trough. Those are real numbers for a real trial, and they are not evidence for the short-acting molecule in this vial, which has no primary human pharmacokinetic, dosing, or safety trial of its own.

Ipamorelin supplies the ghrelin-receptor signal. It is a selective agonist of GHS-R1a — the receptor the hunger hormone ghrelin acts on — derived from the earlier secretagogue GHRP-1 by removing a central Ala-Trp dipeptide. Its founding study described it as the first GHS-receptor agonist with a selectivity for GH release similar to GHRH's, and in conscious swine it did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even well above its GH-releasing dose — the clean profile that separates it from GHRP-2 and GHRP-6. In humans, a single intravenous dose produced one GH secretory episode peaking near 40 minutes and declining exponentially, with a terminal half-life around 2 hours and dose-proportional pharmacokinetics. Its Phase II trial, for post-operative ileus, was well tolerated but did not beat placebo on its efficacy endpoint, and the human data are intravenous throughout — there is no validated subcutaneous human dose.

Why the two are combined is receptor complementarity, and it is the reason this blend has a mechanistic rationale the repair blends don't. The GHRH input primes the somatotroph and raises cAMP; the ghrelin-receptor input triggers IP3/DAG signaling in the same cell. Together they reproduce the body's own two-signal trigger and are described as producing a pulse larger than either alone — which is precisely why these two peptides are co-injected from separate vials in the first place. Two honest limits sit alongside that. First, the synergy is reasoned from receptor pharmacology, not measured in a head-to-head trial, and no published study has tested the co-formulated vial in any model at any ratio; the 5 mg + 5 mg recipe is a market convention, not a studied formulation. Second, the fixed 1 : 1 is close to but not identical with how the two are dosed separately: at 200 mcg of each, Ipamorelin sits in the middle of its own 200–300 mcg standard band while the GHRH half runs at twice the 100 mcg per-dose figure its own page gives. That is not a hazard so much as a fact to know — community protocols simply run both at 100–300 mcg, and titrating up from 100 mcg of each is the norm.

Sources:PubChem CID 91976842 PubChem CID 91971820 PubChem CID 9831659 PMID 16352683 PMID 17018654 PMID 15817669 PMID 9849822 PMID 10496658 PMID 25331030

Why people reach for it

Potential benefits

This is the blend people reach for when growth hormone is the goal and two vials at the same bedtime slot is the obstacle. Here's what draws them to it.

A bigger GH pulse than either peptide alone — The whole point of the pairing: the GHRH receptor and GHS-R1a are two distinct docking sites on the same pituitary somatotroph, and stimulating both at once is described as producing a synergistic pulse rather than an additive one — the same two-signal logic the body uses to fire its own bursts.
Raise your own growth hormone, not inject it — Both halves signal the pituitary to release the body's own GH rather than replacing it from outside, so the natural pulse rhythm and feedback loop stay in the picture — the property that draws people to secretagogues over exogenous hormone.
The clean GHRP half, without the hunger and prolactin — Ipamorelin is the selective member of the GHRP family: in animal studies it releases GH with a selectivity rivaling GHRH while leaving cortisol, ACTH, and prolactin essentially untouched, which is why it is the GHRP that pairs into this blend instead of GHRP-2 or GHRP-6.
Leaner body composition, recovery, and sleep quality — The GH/IGF-1 rise is what people run this pair for — body-composition and training-recovery goals where IGF-1 drives protein synthesis, plus the sleep-quality effect users report from a bedtime dose landing on the deep-sleep GH window.
One draw instead of two, at the one time that matters — The practical reason the blend exists: both peptides need the same fasted bedtime slot anyway, so a single vial, a single reconstitution, and a single injection replace two of everything — and the pair is normally co-drawn into one syringe regardless.
A ratio that nearly matches the separate doses — with one honest asterisk — At 4 units both halves land on their own page's figure (100 mcg each). At the common 8 units, Ipamorelin sits at the floor of its 200–300 mcg standard band while the GHRH half runs at twice its 100 mcg per-dose convention — worth knowing before you assume the vial reproduces two separate protocols exactly.

Sources:PMID 16352683 PMID 17018654 PMID 9849822 PMID 10496658 PMID 25331030

What people reach for this blend for, drawn from what each component's research reports — the human GH/IGF-1 figures belong to the DAC form of CJC-1295 and Ipamorelin's human data are intravenous — and how the pair is used. No study has tested the co-formulated vial, and none of this is a proven outcome or a medical claim.

Implied timing

Best time to dose

Implied best time

Bedtime (empty stomach)

Inject this blend at bedtime on an empty stomach — both component pages make the same call, and the fasted window matters more than the exact hour.

Both halves amplify the body's own GH release, and the single largest natural GH pulse fires in early slow-wave (deep) sleep — a bedtime dose stacks the peptides' pulse on top of that nocturnal surge instead of competing with it.
Food is the reason for the empty stomach: a meal raises insulin and somatostatin (GH's off-switch), both of which blunt the pulse, so the dose goes roughly 2 hours clear of eating. This is the single most important execution variable on the page — a mistimed meal costs more than a mistimed dose.
Both molecules are short-acting — the no-DAC GHRH form is reported to clear in about 30 minutes and Ipamorelin's terminal half-life is around 2 hours, with GH peaking near 40 minutes — so the value is in the discrete pulse each injection triggers, which is why placing that pulse at the overnight recovery window is where it lands best.
On a 2–3× daily schedule a fasted morning dose (before cortisol has fully risen) and a pre-workout dose are the common second and third injections, but the bedtime dose is the anchor in every protocol.

No study establishes an ideal time of day for this blend or for either component — this is reasoned from their GH-secretagogue mechanism and how the pair is used. As a rule of thumb peptide dosing lands in the midday-to-evening window; for GH secretagogues the lean is bedtime, fasted, and that exception is mechanism-driven.

Sources:PMID 16352683 PMID 10496658

How to run it

Dosing & protocol

Dose this blend as one subcutaneous injection measured as total blend on a U-100 insulin syringe, at bedtime, on an empty stomach with roughly a 2-hour food window either side — that fasted bedtime slot is the single most important execution choice, because insulin and somatostatin from a meal directly blunt the GH pulse the injection triggers. The second defining fact is that a blend dosed to one component fixes the other: pick the units and the 1 : 1 ratio decides both halves. The tiers below are built from the two component pages' own ranges so you can see, at each draw size, what each peptide is doing relative to its own convention. Before any of it, check the label says no DAC — the whole schedule below assumes the short-acting form.

Community convention, not trial-proven: no study has tested the co-formulated CJC-1295 + Ipamorelin vial, the no-DAC form has no primary human trial, and Ipamorelin's human data are intravenous with a Phase II trial that failed its efficacy endpoint. Neither component is FDA-approved and both are WADA S2 prohibited — every number here is a usage pattern assembled from the component pages, not a medical recommendation.

Tiered dose ranges (total blend per draw)

Standard mix: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL, so 1 unit on a U-100 syringe = 50 mcg of blend (25 mcg CJC-1295 no-DAC + 25 mcg Ipamorelin).

Low / titration — 4 units (200 mcg):: 100 mcg CJC-1295 (no DAC) + 100 mcg Ipamorelin once daily at bedtime. This is the one draw where both halves sit exactly on their own page's number: 100 mcg is CJC-1295 no-DAC's per-dose convention, and 100–150 mcg is Ipamorelin's low band. Start here for the first week, then work up — titration is the norm with this pair, not an abundance of caution.
Standard — 8 units (400 mcg):: 200 mcg of each once daily at bedtime — the common dose and this page's calculator default. Ipamorelin lands on the opening figure of its own 200–300 mcg standard band — its page's own calculator default — while the GHRH half lands at twice the 100 mcg per-dose figure its page gives. That asymmetry is the blend's built-in trade-off, and it is what makes the vial work in practice: community protocols for this pair simply run both peptides at 100–300 mcg, so 200 mcg of each is squarely inside how it is actually used — it just isn't two separate protocols reproduced exactly.
High / escalation — 8–12 units (400–600 mcg), 2–3× daily:: 200–300 mcg of each per injection, two or three times daily, each dose on an empty stomach and spaced roughly 4–6 hours apart (typically bedtime + fasted AM, sometimes + pre-workout). Read the escalation correctly: both component pages describe the higher tier as more injections, not a bigger shot — Ipamorelin's own high tier is the same 200–300 mcg at greater frequency, and CJC-1295 no-DAC is dosed 1–3× daily at a flat 100 mcg. A 2–3× daily schedule also empties a 10 mg vial in roughly one to two weeks, which is the practical constraint most people hit first.

Subcutaneous administration

Injected into subcutaneous fat as a single draw; site rotation, the fasted window, and a consistent bedtime slot are the only execution choices.

Injection site:: Abdomen (2–3 cm clear of the navel), the love-handle area, or the outer thigh. Rotate sites between doses to prevent local irritation and lipohypertrophy — small fatty lumps from repeated injections in one spot. Neither peptide acts locally, so the site is about tolerance, not targeting.
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. At the standard 10 mg + 2 mL mix: 4 units = 200 mcg · 8 units = 400 mcg · 10 units = 500 mcg · 12 units = 600 mcg of blend, each split evenly between the two peptides. The calculator on this page shows what any draw contains of each component, for any vial size or water volume.
Time of day:: Bedtime — see Best time to dose above. On a twice-daily schedule the second dose is a fasted morning injection before breakfast; on a three-times-daily schedule the third is pre-workout. The bedtime dose is the anchor in every version, because it is the one that lands on the body's largest natural GH pulse.
Food window:: At least 90–120 minutes after your last meal before injecting, and avoid carbohydrate- or fat-heavy food for about 2 hours after. Insulin and somatostatin both rise with food and both suppress the GH pulse. This is the rule that separates a working protocol from a wasted one — keep any bedtime cofactors to capsules and water rather than a snack.

Cycle & washout

Run it in blocks, not indefinitely — the reasoning on both component pages is that continuous stimulation may dull pituitary responsiveness, and a break is thought to reset it.

Standard cycle:: 8–12 weeks of daily bedtime dosing, the block length both component pages give. At 8 units a day that is roughly two to three and a half vials, since one 10 mg vial holds about 25 doses at the standard draw (about three to four weeks).
Washout:: 4–6 weeks off between cycles, taking the longer of the two component pages' figures. GH and IGF-1 drift back toward baseline during the break; measuring IGF-1 at the end of a cycle, before the washout, is the useful checkpoint.
Lab check:: IGF-1 is the marker for both halves. A baseline before starting and a re-check at 6–8 weeks shows whether the signal is landing; an IGF-1 above the age-adjusted reference range is the signal to reduce the dose or pause. Because the blend is 1 : 1, reducing means lowering the whole draw — there is no way to pull back one peptide alone.
Vial life:: One 10 mg vial is about 25 doses at 8 units and 50 at 4 units; at 12 units three times daily the same vial is gone in under a week. Keep the reconstituted vial refrigerated and finish it within about four weeks — at the standard dose the vial runs out first anyway.

Reconstitution at a glance

The on-page calculator does this live and splits every draw in two; the quick reference for the standard 10 mg vial:

Mixing (2 mL — the standard convention):: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL. On a 100-unit (1 mL) U-100 insulin syringe: 1 unit = 50 mcg of blend (25 mcg of each) · 4 units = 200 mcg (100 mcg each) · 8 units = 400 mcg (200 mcg each) · 12 units = 600 mcg (300 mcg each).
Mixing (3 mL — finer increments):: 10 mg + 3 mL = 3,333 mcg/mL, so 1 unit ≈ 33 mcg of blend (≈ 17 mcg of each). The same doses land on 6 units (100 mcg each), 12 units (200 mcg each), and 18 units (300 mcg each) — more syringe marks per dose, which reduces measuring error while titrating. Either mix works; just don't switch water volume mid-vial without redoing the math.
Why the split matters more than the total:: The syringe measures total blend, but each peptide's dose logic lives on its own page. The calculator's per-component readout is the number to compare against CJC-1295 and Ipamorelin. The split assumes the standard 5 mg + 5 mg recipe — if your label lists a different ratio, this page's arithmetic doesn't apply to it.
The label check that comes first:: Confirm the vial says no DAC (or Mod-GRF 1-29). A 1 : 1 blend built on the DAC form is a schedule mismatch, not a dosing preference: the DAC molecule is run at roughly 1–2 mg once weekly, so in a 1 : 1 vial matching it means injecting 1–2 mg of Ipamorelin at once — three to ten times its own 200–300 mcg per-dose figure, about a week's worth in a single shot. If the label says "with DAC," nothing on this page describes how to run it.

Sources:PMID 16352683 PMID 17018654 PMID 9849822 PMID 10496658 PMID 25331030

Substrate the signal needs

Nutritional cofactor precision

Both halves of this blend do the same job from two directions: make the pituitary fire a bigger GH pulse. That sets the cofactor agenda — relieve somatostatin, GH's own off-switch, so the pulse runs longer; offset the one real cost of elevated GH, a transient rise in blood glucose; and supply the protein and minerals the GH/IGF-1 signal needs to build anything. Ipamorelin's selectivity means there is less to mitigate here than with GHRP-2 or GHRP-6 — the amplify group is the main lever.

Reasoned from GH-axis physiology and the two components' mechanisms — not a blend-specific cofactor study. Supplement doses are common community ranges, not findings about this blend.

AMPLIFY / relieve the somatostatin brake

Somatostatin is GH's off-switch. Lowering its tone gives the same injection more room to work.

L-arginine:: 3–6 g taken 30–60 minutes before the bedtime injection. Arginine suppresses somatostatin release from the hypothalamus, widening the window for GH output. Take it on an empty stomach — which the fasted dosing window already requires — and not with a high-fat meal, which blunts absorption.
Glycine:: 3–10 g at bedtime. Associated with reduced somatostatin tone, and it improves slow-wave sleep quality — which directly protects the natural nighttime GH pulse this blend is timed to amplify. The one cofactor that helps twice.
Alpha-GPC:: 300–600 mg taken 30–60 minutes before the injection. Raises acetylcholine, which stimulates GH release through a separate hypothalamic pathway and further suppresses somatostatin — most relevant here because every dose of this blend is a discrete pulse whose amplitude is the whole point.

MITIGATE the cost — the GH-driven glucose rise

Elevated GH transiently raises blood glucose and lowers insulin sensitivity. That is the one cost worth managing across a multi-week block.

Berberine:: 500 mg with meals, 2–3× daily. Activates AMPK, the cell's fuel-sensing switch, and supports insulin sensitivity — a practical first-line counter to the glucose effect of a sustained GH-elevating cycle. Take it with food, deliberately away from the injection, since you want insulin low at dose time.
Alpha-lipoic acid (ALA):: 300–600 mg with a meal. Increases glucose uptake into muscle via GLUT4 translocation, with antioxidant effects that support mitochondrial function under anabolic load. Meal timing, not fasted-dose timing.
Magnesium glycinate:: 300–400 mg elemental magnesium before bed. Supports insulin receptor signaling, and the glycinate form supports deep sleep — the window in which the largest natural GH pulse occurs, and the one this blend is dosed to ride. Capsules and water only; a bedtime snack undoes the fasted window.

SUPPLY the substrate — protein and GH-axis minerals

GH and IGF-1 are instructions to synthesize protein and remodel tissue. Without the raw material, the signal has nothing to build from.

Dietary protein:: 1.6–2.0 g per kg of body weight per day (≈ 0.7–0.9 g per lb), spread across 3–4 meals. IGF-1's primary job is to drive protein synthesis, so leucine-rich sources matter most — but keep the last meal clear of the injection window, which is the one place this cofactor and the dosing rule can collide.
ZMA (zinc + magnesium + vitamin B6):: Zinc 25–30 mg + magnesium 400–500 mg + vitamin B6 10 mg, 30–60 minutes before bed on an empty stomach. Low zinc tracks with lower IGF-1 and B6 supports GH synthesis; taken as capsules it fits inside the fasted window rather than breaking it. Don't take it alongside calcium, which competes for absorption.
Vitamin D3 + K2:: Vitamin D 2,000–5,000 IU daily, dosed to a blood level in the sufficient range (typically 40–60 ng/mL), plus vitamin K2 100–200 mcg. Vitamin D associates with healthy IGF-1 levels and musculoskeletal tissue quality; K2 directs calcium to bone rather than soft tissue during a GH-driven remodeling phase.

Sources:PMID 16352683 PMID 9849822 PMID 10496658

Combinations + timing

Stacking notes + timing windows

This vial already contains the canonical stack — one GHRH analog and one GHRP, the two-signal pair. That makes the useful additions come from a completely different axis, and it makes most of the obvious GH-shelf additions redundant: a second GHRH analog or a second GHRP is the same lever twice, which is the single most common mistake with this blend.

User combinations reasoned from complementary mechanisms — not regimens studied head-to-head, and the blend itself has never been studied. Doses are community convention; "reached for" describes where users go, not a proven indication.

The blend + BPC-157 / TB-500 (or a repair blend)

The genuinely complementary addition — local tissue repair under a systemic anabolic backdrop.

Why it works:: BPC-157 promotes angiogenesis and tendon, ligament, and gut-lining repair; TB-500 drives repair-cell migration into damaged tissue. Neither touches the GH axis, so they add a lever this blend doesn't have: the GH/IGF-1 rise supplies the systemic anabolic environment while those two work locally on the structure being rebuilt. Three different mechanisms, no overlap.
The protocol:: The blend 8 units at bedtime, plus BPC-157 250–500 mcg subcutaneously once daily and TB-500 on its own loading/maintenance schedule (typically a higher weekly dose for the first 4–6 weeks, then maintenance) — or run the pre-mixed Wolverine Blend or GLOW Blend instead of two more vials. Rotate sites; the repair peptides don't share the blend's fasted-window rule, so their timing is free.
Outcome:: Reached for on soft-tissue injuries, post-surgical recovery, and training wear where both an anabolic environment and direct tissue repair are wanted at once.

What NOT to stack: a second GHRH analog or a second GHRP

The blend already holds one of each. Adding another of either pushes the same receptor twice.

Why a second GHRH analog is redundant:: Tesamorelin and Sermorelin are GHRH-receptor agonists — the same receptor the CJC-1295 half occupies. Adding one opens no new pathway; it just increases load on a receptor that is already being driven, without the two-signal amplification that comes from a partner on a different receptor. The correct second signal is a GHRP, and this vial already has it.
Why a second GHRP is worse than redundant:: GHRP-2, GHRP-6, and Hexarelin all act at GHS-R1a, the same receptor as the Ipamorelin half — same lever again. They also bring back the appetite spike, the prolactin rise, and the cortisol response that Ipamorelin was chosen to avoid, so the trade is a duplicated signal for a dirtier endocrine profile.
The honest call:: If a protocol adds Sermorelin, Tesamorelin, GHRP-2, or GHRP-6 on top of this blend, that is a marketing stack rather than a mechanistic one. The blend is complete on its own axis; look to a different axis for the next addition.

The blend + a separate vial — un-fixing the 1 : 1

When you want a different split than the vial gives, the answer is a top-up, not a bigger draw.

Why it works:: The 1 : 1 is the blend's only real constraint: raising the Ipamorelin side to the top of its 200–300 mcg standard band also pushes the GHRH half to 300 mcg, three times the 100 mcg per-dose figure on CJC-1295's own page. A separate Ipamorelin vial lets you move one number without the other — the same reasoning that sends people back to single vials from any fixed-ratio blend.
The protocol:: The blend 4 units (100 mcg of each) at bedtime, plus separate Ipamorelin 100–200 mcg co-drawn into the same syringe, giving 200–300 mcg of Ipamorelin against 100 mcg of the GHRH half — the split the two component pages describe. The simpler alternative is to skip the blend entirely and run two vials; the blend earns its place on convenience, so if you are already carrying a second vial, the reason for the blend is mostly gone.
Outcome:: Reached for by people who ran the components separately first and want to keep that split, and by anyone whose response plateaus at a draw size where the GHRH half has run ahead of its own convention.

Sources:PMID 9849822 PMID 16352683 PMID 10496658

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

This dose contains

CJC-1295 (no DAC)200 mcg
Ipamorelin200 mcg

Fixed ratio — every draw carries all of the vial's peptides in the same proportions; only the total changes.

Volume per dose: 0.08 mL
Doses per vial: 25
Concentration: 5 mg/mL

One vial lasts

Daily: 25 days
Every other day: 50 days
5×/week: 35 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no safety study of this blend, so the safety picture is the two component pictures laid side by side. Ipamorelin has the stronger of the two: in its Phase II trial, intravenous dosing at 0.03 mg/kg twice daily for up to seven days was reported as well tolerated across 114 surgical patients, with safety assessed by adverse-event monitoring and laboratory tests, and the supporting swine data found no significant elevation of ACTH, cortisol, prolactin, or the gonadotropins even above its GH-releasing dose. No formal long-term toxicology dossier was located for it. For CJC-1295, the early human trials of the DAC form reported it as safe and relatively well tolerated, particularly at 30–60 µg/kg subcutaneously, with injection-site reactions commonly cited for the class — but those are the DAC molecule's data, and the no-DAC form in this vial has no primary safety trial at all.

One program-level event belongs on the record. A 2006 Phase 2 trial of CJC-1295 in HIV-associated lipodystrophy was halted after a participant died, with the cause of death and its relationship to the study drug reported as under investigation at the time; the developer later discontinued development. That account comes from secondary reporting rather than a primary trial publication, no causal link to the drug was established, and it concerns the DAC form — it is neither evidence against nor evidence for the short-acting molecule in this blend. There is no long-term human safety data for either form.

Two cautions are specific to running these two as one fixed-ratio vial. First, you cannot adjust one component without moving the other: if a dose produces an effect you want to dial back, the only lever is the whole draw or a switch to separate vials. Second, the class effect is metabolic rather than local — elevated GH transiently raises blood glucose and lowers insulin sensitivity, which is worth watching on an 8–12-week block, and IGF-1 climbing above the age-adjusted reference range is the standard signal to reduce or pause. The practical complaints users report are the ordinary ones: injection-site redness or soreness, and the deeper or heavier sleep a bedtime GH pulse can bring. Both components are prohibited in sport by WADA (S2) at all times. This safety picture is assembled from two separate, short-term datasets — one intravenous, one for a different molecule — and none of it is human trial evidence for subcutaneous use of this blend.

Sources:PMID 25331030 PMID 9849822 PMID 16352683 aidsmap 2006 PMID 10496658 WADA

As reported in literature

Research dosing ranges

There is no research dose for this blend because there is no research on this blend: no published study has tested CJC-1295 and Ipamorelin as a co-formulated vial. What exists is two separate evidence bases, and the practical figures above lean on each component page's cited ranges. The rows below pull the load-bearing study doses from those pages so the evidence is visible here — shown separately so research data is never mistaken for a human dose, and labeled by form, because every CJC-1295 human row belongs to the DAC molecule and not to the no-DAC form this vial contains. Doses are per kilogram of body weight (1 kg ≈ 2.2 lb) where the studies report them that way; Ipamorelin's human rows are intravenous.

Dose	Route	Model	Outcome	Sources:
Any	Subcutaneous	— no study of the two-peptide blend	No published study has tested CJC-1295 + Ipamorelin as one co-formulated vial; the 5 mg + 5 mg recipe is a market convention, not a studied formulation
None located	Subcutaneous	— no primary trial of CJC-1295 no-DAC (Mod-GRF 1-29)	No primary human pharmacokinetic, dosing, or safety trial was located for the short-acting no-DAC form — the form this blend contains; its ~30 min clearance is secondary-sourced
30–60 µg/kg	Subcutaneous	Human (CJC-1295 WITH DAC; healthy, 21–61 y)	GH up 2–10× for ≥6 d; IGF-1 up 1.5–3× for 9–11 d; best-tolerated 30–60 µg/kg — the DAC molecule, not the form in this vial	PMID 16352683
60–90 µg/kg	Subcutaneous	Human (CJC-1295 WITH DAC; healthy men)	Preserved GH pulsatility; trough GH +7.5×, mean GH +46%, IGF-1 +45% — the DAC molecule, not the form in this vial	PMID 17018654
Single injection	Injection	Rat (CJC-1295 WITH DAC; Sprague-Dawley)	Plasma detectable >72 h; ~4× GH AUC over 2 h vs native GHRH	PMID 15817669
EC50 1.3 nmol/L	In vitro	Rat pituitary cells (Ipamorelin)	GH release (Emax ~85%)	PMID 9849822
ED50 ~2.3 nmol/kg	Intravenous	Swine, conscious (Ipamorelin)	GH release; no FSH, LH, prolactin or TSH change; ACTH/cortisol not significantly different from GHRH stimulation	PMID 9849822
4.21–140.45 nmol/kg	IV infusion (15 min)	Human (Ipamorelin; healthy, n=8/dose)	Dose-proportional GH release; t½ ~2 h	PMID 10496658
0.03 mg/kg twice daily	Intravenous	Human (Ipamorelin; Phase II, n=114)	Well tolerated; failed efficacy endpoint	PMID 25331030

Quick answers

Frequently asked

What exactly is in a CJC-1295 / Ipamorelin vial?

The standard 10 mg vial contains 5 mg of CJC-1295 in its no-DAC form (chemically Mod-GRF 1-29) and 5 mg of Ipamorelin, freeze-dried together in a fixed 1 : 1 ratio by weight. It is a packaging of two known peptides, not a new molecule. Other vial sizes exist — check the label's ratio, because this page's arithmetic assumes 5 mg + 5 mg.

Is the CJC-1295 in a blend the DAC form or the no-DAC form?

The no-DAC form (Mod-GRF 1-29), and the reason is scheduling arithmetic rather than preference. The DAC molecule binds albumin, has a half-life of roughly 5.8–8.1 days, and is dosed about 1–2 mg once weekly; the no-DAC molecule clears in about 30 minutes and is dosed 100 mcg one to three times daily, always with a GHRP. A 1 : 1 vial run on a weekly schedule would deliver 1–2 mg of Ipamorelin in a single injection — three to ten times its 200–300 mcg per-dose figure, roughly a week's worth at once, which is not how Ipamorelin is used. If a 1 : 1 Ipamorelin blend's label says "with DAC," the two schedules are incompatible and none of this page's math applies to it.

How much of each peptide is in 8 units?

At the standard mix (10 mg + 2 mL bacteriostatic water = 5,000 mcg/mL), 8 units on a U-100 insulin syringe is 400 mcg of blend: 200 mcg of CJC-1295 no-DAC and 200 mcg of Ipamorelin. Each single unit is 50 mcg of blend, or 25 mcg of each. The calculator on this page shows the split for any draw, vial size, or water volume.

Why are these two peptides blended together at all?

Receptor complementarity, and it is a better reason than most blends have. CJC-1295 activates the GHRH receptor and Ipamorelin activates GHS-R1a, the ghrelin receptor — two different docking sites on the same pituitary somatotroph. Stimulating both at once is described as producing a larger GH pulse than either alone, mirroring the body's own two-signal release, which is why these two are co-injected from separate vials in the first place. The blend just puts that pairing in one bottle. The honest limit: the synergy is reasoned from receptor pharmacology rather than measured in a head-to-head trial, and no study has tested the co-formulated vial.

Does the 1 : 1 ratio match how the two are dosed separately?

Closely, but not exactly. CJC-1295 no-DAC's own page gives 100 mcg per dose, one to three times daily; Ipamorelin's gives 100–150 mcg low and 200–300 mcg standard. At 4 units (100 mcg of each) both halves land on their own numbers. At the common 8 units, Ipamorelin sits at the floor of its standard band while the GHRH half runs at twice its per-dose figure. Community protocols for this pair simply run both at 100–300 mcg, so the vial matches practice — it just isn't two separate protocols reproduced exactly, which is worth knowing before you assume it is.

Is this blend an approved drug?

No. Neither component is an approved drug, no trial has ever tested the combination as one vial, the no-DAC form of CJC-1295 has no primary human trial, and Ipamorelin's human data are intravenous with a Phase II trial that failed its efficacy endpoint. Both are prohibited in sport by WADA at all times. This page presents research literature and community usage only and makes no therapeutic claims.

Primary sources

References

PubChem CID 91976842PubChem CID 91976842 (CJC-1295 without DAC / Mod-GRF 1-29)
PubChem CID 91971820PubChem CID 91971820 (CJC-1295 with DAC)
PubChem CID 9831659PubChem CID 9831659 (Ipamorelin)
PMID 16352683J Clin Endocrinol Metab 2006 (CJC-1295 human PK/PD/safety, multi-day GH/IGF-1)
PMID 17018654J Clin Endocrinol Metab 2006 (preserved GH pulsatility under continuous stimulation)
PMID 15817669Endocrinology 2005 (hGRF(1-29)-albumin bioconjugate; original CJC-1295 ID, rat)
PMID 9849822Raun et al., Eur. J. Endocrinol. 1998
PMID 10496658Gobburu et al., Pharm. Res. 1999 (human PK)
PMID 25331030Beck et al., Int. J. Colorectal Dis. 2014 (Phase II)
NCT00672074ClinicalTrials.gov NCT00672074 (Phase II ileus)
aidsmap 2006aidsmap (Jul 2006) — Phase 2 lipodystrophy trial halted after participant death
FDAFDA — bulk drug substances under section 503A (Category 2 history)
FDA 2024FDA PCAC briefing — Ipamorelin (2024)
WADAWADA Prohibited List (S2 — GHRH analogues and growth-hormone secretagogues prohibited at all times)

Reviewed by Ki Researcher Team · Research use only · Not medical advice · Updated 2026-09-01